Evidence map›Paper›PMID 32582547›Full record

ArticleFrontiers in oncology2020

Association of DNA-Methylation Profiles With Immune Responses Elicited in Breast Cancer Patients Immunized With a Carbohydrate-Mimicking Peptide: A Pilot Study.

Cinthia Violeta Hernandez Puente, Ping-Ching Hsu, Lora J Rogers, Fariba Jousheghany, Eric Siegel, Susan A Kadlubar, J Thaddeus Beck, Issam Makhoul, Laura F Hutchins, Thomas Kieber-Emmons and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Methods in DNA methylation array dataset analysis: A review.Computational and structural biotechnology journal · 2024
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Cinthia Violeta Hernandez PuenteDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Ping-Ching HsuDepartment of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Lora J RogersDivision of Medical Genetics, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Fariba JousheghanyDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Eric SiegelDepartment of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Susan A KadlubarWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
J Thaddeus BeckHighland Oncolgy Group, Fayetteville, AR, United States.
Issam MakhoulWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Laura F HutchinsWinthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Thomas Kieber-EmmonsDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Behjatolah Monzavi-KarbassiDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
University of Arkansas for Medical Sciences · USWinthrop Rockefeller Foundation · USHighlands Oncology Group · US

Funding

Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Arkansas Center for Clinical and Translational ResearchUL1TR000039 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI BECK, CORNELIA MARIE, JAMES, LAURA P · 2012 to 2014
$10.0M
NCATS NIH HHS UL1 TR000039NIGMS NIH HHS P20 GM103625
6 · The paper itself

Abstract

Immune response to a given antigen, particularly in cancer patients, is complex and is controlled by various genetic and environmental factors. Identifying biomarkers that can predict robust response to immunization is an urgent need in clinical cancer vaccine development. Given the involvement of DNA methylation in the development of lymphocytes, tumorigenicity and tumor progression, we aimed to analyze pre-vaccination DNA methylation profiles of peripheral blood mononuclear cells (PBMCs) from breast cancer subjects vaccinated with a novel peptide-based vaccine referred to as P10s-PADRE. This pilot study was performed to evaluate whether signatures of differentially methylated (DM) loci can be developed as potential predictive biomarkers for prescreening subjects with cancer who will most likely generate an immune response to the vaccine. Genomic DNA was isolated from PBMCs of eight vaccinated subjects, and their DNA methylation profiles were determined using Infinium

Indexed as

breast cancercancer vaccineDNA methylationimmune responsepilot study

Identifiers

PMID32582547
PMCPMC7290046
OpenAlexW3033963084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.